Amylyx Pharmaceuticals, Inc. (AMLX)
34.10
+0.14
(+0.41%)
USD |
NASDAQ |
Sep 04, 16:00
34.12
+0.02
(+0.07%)
After-Hours: 20:00
Amylyx Pharmaceuticals SG&A Expense (TTM) : 69.66M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 69.66M |
| March 31, 2026 | 63.37M |
| December 31, 2025 | 62.89M |
| September 30, 2025 | 64.59M |
| June 30, 2025 | 66.25M |
| March 31, 2025 | 72.26M |
| December 31, 2024 | 114.33M |
| September 30, 2024 | 149.48M |
| June 30, 2024 | 180.36M |
| March 31, 2024 | 202.11M |
| December 31, 2023 | 188.36M |
| September 30, 2023 | 176.96M |
| Date | Value |
|---|---|
| June 30, 2023 | 158.18M |
| March 31, 2023 | 144.78M |
| December 31, 2022 | 127.13M |
| September 30, 2022 | 101.20M |
| June 30, 2022 | 71.26M |
| March 31, 2022 | 48.93M |
| December 31, 2021 | 28.58M |
| September 30, 2021 | 17.59M |
| June 30, 2021 | 17.59M |
| March 31, 2021 | 9.933M |
| December 31, 2020 | 3.929M |
| September 30, 2020 | 0.00 |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Pfizer Inc. | 13.72B |
| Eli Lilly & Co. | 12.24B |
| Merck & Co., Inc. | 11.14B |
| EyePoint, Inc. | 55.41M |
| Bristol Myers Squibb Co. | 7.413B |